BetaStem Therapeutics Inc Profile last edited on: 11/18/2019
CAGE: 4LN86
UEI: MK9RVWH59CV3
Business Identifier: Autologous Stem Cell Therapy for Diabetic Retinopathy 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2 Lower Crescent Avenue Suite 2
Sausalito, CA 94965
Sausalito, CA 94965
| (415) 913-7595 |
| bartelmezsh@yahoo.com |
| www.betastemtherapy.com |
Location: Single
Congr. District: 02
County: Marin
Congr. District: 02
County: Marin
Public Profile
Seemingly rebuilding on the endeavor that had previously been in San Francisco and appeared to have been close down, management re-entered the SBIR arena in 2017. That recent effort organized around use of "physiologic" hematopoietic stem cells (naturally occurring stem cells from the bone marrow or blood. Not human embryonic, huES, or induced pluipotent, iPS, stem cells) from the patient to treat vascular damage in the eye, the heart and peripheral vessels, primarily as a result of chronic diabetes. Ex vivo, transiently modified human autologous peripheral blood, bone marrow and cord blood hematopoietic stem cells. Google lists the firm (2019) as permanently closed and the website is gone.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2017 | 1 | NIH | $461,417 | |
| Project Title: Autologous TGFB1 Modified CD34+ Stem Cells for Repair of Diabetic Macular Edema and Macular Ischemia | ||||
| 2009 | 1 | NIH | $496,925 | |
| Project Title: A Cellular Approach to the Treatment of Diabetic Maculopathy | ||||
| 2009 | 1 | NIH | $284,989 | |
| Project Title: Accelerated Repair Of Vascular Injury In Diabetes By Tgf-Beta Modified Stem Cells | ||||
| 2009 | 1 | NIH | $326,697 | |
| Project Title: Autologous Tgf-B-Modified Hsc For Repair Of Vasodegenerative Diabetic Retinopathy | ||||
| 2007 | 1 | NIH | $198,752 | |
| Project Title: Progenitor assay to screen proteins/molecules for treatment of type1 diabetes | ||||
Key People / Management
Stephen H Bartelmez -- President
Charles Garcia -- Chief Medical Officer
Leland Johnson -- Director of Business Development and Corporate Strategy
Robert Martinsons -- VP Marketing & Business
Charles Garcia -- Chief Medical Officer
Leland Johnson -- Director of Business Development and Corporate Strategy
Robert Martinsons -- VP Marketing & Business
